ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
The Complex Interplay Between Dyslipidemic Subjects Living with Type 2 Diabetes and Metabolic Syndrome and Statin Treatment: A Reflection on Adherence and Persistence in the Real World.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHigh levels of blood cholesterol are a major risk factor for atherosclerotic cardiovascular disease and require early and consistent utilization of statins as first-line medications to avoid disabling or even deadly consequences. Nevertheless, real-world treatment adherence is significantly lower than that reported in clinical trials. The present paper aims to improve understanding of the reasons behind this phenomenon to help physicians reduce morbidity, mortality, and healthcare costs by reversing this trend.
methodsWe conducted a real-life, observational, noninterventional, retrospective, multicenter study of statin prescription, adherence, persistence, potential side effects, and the rate of early discontinuation in 1959 individuals with type 2 diabetes mellitus (T2D), metabolic syndrome (MS), and moderate hypercholesterolemia, free of prior cardiovascular events in the observation period 2023-2025. In greater detail, we assessed three main areas: the history and features of the underlying pathology-understood as the "clinical condition"-the knowledge and beliefs, and the socioeconomic status of the patients by analyzing anonymized clinical records from the databases routinely used in our joint network units.
resultsDeterminants significantly associated with insufficient or no adherence in the first area included older age, complex therapy involving multiple medications, and a history of myalgias and joint pain. In the second area, significant factors were low education, income levels, widowed/divorced, retired/unemployed conditions, and living alone. Finally, in the third area, a lack of awareness regarding cardiovascular disease (CVD) risk, previous negative experiences with statins, negative influence from social media, fear of side effects, a general rejection of medications, and a preference for "natural supplements," along with the belief that diet is sufficient and that therapy is of short duration, were identified.
conclusionsOur results prompted the decision to follow up with a prospective phase in which as many subjects as possible from this cohort will be contacted and interviewed to verify the consistency of the observations and to explore adherence further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.